Altium Capital Management LP - ALPINE IMMUNE SCIENCES INC ownership

Quarter-by-quarter ownership
Altium Capital Management LP ownership history of ALPINE IMMUNE SCIENCES INC
ValueSharesWeighting
Q1 2024$3,085,895
+105.7%
77,848
-1.1%
1.22%
+19.8%
Q4 2023$1,500,46078,7231.02%
Other shareholders
ALPINE IMMUNE SCIENCES INC shareholders Q2 2024
NameSharesValueWeighting ↓
Decheng Capital LLC 7,083,288$135,007,46937.72%
Lynx1 Capital Management LP 3,813,926$72,693,42928.58%
GREAT POINT PARTNERS LLC 3,703,433$70,587,43312.03%
Ally Bridge Group (NY) LLC 357,271$6,809,5854.06%
Octagon Capital Advisors LP 1,241,300$23,659,1783.79%
Exome Asset Management LLC 173,500$3,306,9103.27%
Frazier Life Sciences Management, L.P. 3,131,008$59,677,0123.19%
Nan Fung Group Holdings Ltd 263,940$5,030,6963.13%
Paradigm Biocapital Advisors LP 3,176,743$60,548,7222.84%
COMMODORE CAPITAL LP 1,610,000$30,686,6002.68%
View complete list of ALPINE IMMUNE SCIENCES INC shareholders